Home Cart Sign in  
Chemical Structure| 1638250-96-0 Chemical Structure| 1638250-96-0

Structure of ETC-159
CAS No.: 1638250-96-0

Chemical Structure| 1638250-96-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ETC-159 is a potent, orally available PORCN inhibitor. It inhibits β-catenin reporter activity with an IC50 of 2.9 nM.

Synonyms: ETC-1922159

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ETC-159

CAS No. :1638250-96-0
Formula : C19H17N7O3
M.W : 391.38
SMILES Code : O=C(NC1=NN=C(C2=CC=CC=C2)C=C1)CN3C=NC(N(C)C(N4C)=O)=C3C4=O
Synonyms :
ETC-1922159
MDL No. :MFCD29472267
InChI Key :QTRXIFVSTWXRJJ-UHFFFAOYSA-N
Pubchem ID :86280523

Safety of ETC-159

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HPAF-II cells 100 nM 72 h Wnt inhibition increased cell surface EGFR levels J Clin Invest. 2024 Jan 23;134(6):e171222.
AsPC-1 cells 100 nM 72 h Wnt inhibition increased cell surface EGFR levels J Clin Invest. 2024 Jan 23;134(6):e171222.
143B 100 nM 72 h To evaluate the effect of ETC-159 on angiogenesis in osteosarcoma cells, showing significant reduction in vessel length and surface area Int J Mol Sci. 2023 Mar 1;24(5):4759.
SJSA-1 100 nM 72 h To evaluate the effect of ETC-159 on angiogenesis in osteosarcoma cells, showing significant reduction in vessel length and surface area Int J Mol Sci. 2023 Mar 1;24(5):4759.
HPAF-II cells 100 nM approximately 2 weeks ETC-159 significantly inhibited the growth of HPAF-II cells in 2D culture. J Clin Invest. 2022 Jun 15;132(12):e156305.
PaTu8988T cells 1 µM 48 h To evaluate the effect of ETC-159 on HR and FA pathway gene expression, results showed significant reduction in BRCA1, BRCA2, FANCD2, and RAD51 expression. EMBO Mol Med. 2021 Apr 9;13(4):e13349.
AsPC-1 cells 100 nM 48 h To evaluate the effect of ETC-159 on homologous recombination repair, results showed ~40% reduction in GFP-positive cells. EMBO Mol Med. 2021 Apr 9;13(4):e13349.
HPAF-II cells 100 nM 48 h To evaluate the effect of ETC-159 on HR and FA pathway gene expression, results showed significant reduction in BRCA1, BRCA2, FANCD2, and RAD51 expression. EMBO Mol Med. 2021 Apr 9;13(4):e13349.
PA-1 teratocarcinoma cells 35 nM 24 h Inhibition of endogenous Wnt/β-catenin signaling and soft agar colony formation Oncogene. 2016 Apr 28;35(17):2197-207.
HeLa cells 100 nM 16 h Inhibition of Wnt3A palmitoleation, demonstrating that ETC-159 and ETC-131 block Wnt secretion by preventing the interaction of Wnt with Wntless Oncogene. 2016 Apr 28;35(17):2197-207.
HEK293 cells 2.9 nM 24 h Inhibition of Wnt/β-catenin reporter activity, confirming ETC-159 and ETC-131 as potent and specific inhibitors of Wnt secretion Oncogene. 2016 Apr 28;35(17):2197-207.
BrafV600EPten−/− (BPD6) cells 100 nM 48 h Reversed tumor conditioned media-induced DC-dependent Treg generation Cell Rep. 2021 May 4;35(5):109071.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice HPAF-II subcutaneous xenograft model Oral gavage 5 mg/kg Once daily for 19 days To evaluate the tumor growth inhibition effect of ETC-159 and GDC-0941 combination therapy. The combination treatment significantly suppressed tumor growth, outperforming monotherapy. Oncogene. 2019 Oct;38(40):6662-6677
Mice C57/BL6 mice Oral 3–30 mg/kg Daily or every other day for 4-8 weeks To evaluate the skeletal effects of PORCN inhibitor ETC-159, which resulted in reduced bone volume and density, along with increased bone marrow adipocytes. Concurrent use of alendronate mitigated bone loss. Bone Res. 2018 May 25;6:17
BALB/c nude mice Osteosarcoma xenograft model Oral gavage 30 mg/kg Once daily for 15 days To evaluate the therapeutic effect of ETC-159 on osteosarcoma xenograft models, showing increased tumor necrosis and reduced angiogenesis Int J Mol Sci. 2023 Mar 1;24(5):4759.
NSG mice Patu8988T and Patu8988S xenograft models Oral gavage 15 mg/kg Once every day (q.d.) for several weeks ETC-159 failed to suppress Patu8988T orthotopic tumor growth but significantly inhibited Patu8988S tumor growth. J Clin Invest. 2022 Jun 15;132(12):e156305.
NSG mice HPAF-II xenograft model Oral gavage 37.5 mg/kg Daily administration for 56 hours To evaluate the effect of ETC-159 on HR and FA pathway gene expression, results showed significant reduction in BRCA1, BRCA2, FANCD2, and RAD51 expression. EMBO Mol Med. 2021 Apr 9;13(4):e13349.
BALB/c nude mice MMTV-Wnt1 tumor model Oral gavage 1, 3, 10 mg/kg Once daily for 7 days ETC-159 significantly inhibited tumor growth, promoted relocalization of β-catenin from nucleus and cytoplasm to the membrane, and downregulated Wnt target gene expression Oncogene. 2016 Apr 28;35(17):2197-207.
Mouse BP transgenic melanoma model Oral 200 μg Every 3 days In the autochthonous melanoma model, the ETC-159 PORCN inhibitor stabilized primary tumor progression, increased tumor-infiltrating CD8+ T cells, and reduced the number of tumor-resident Tregs Cell Rep. 2021 May 4;35(5):109071.
Mice HPAF-II orthotopic xenograft model Oral 30 mg/kg Once daily for 28 days ETC-159 significantly inhibited the growth of HPAF-II orthotopic xenografts and led to pronounced histomorphological changes. J Clin Invest. 2018 Dec 3;128(12):5620-5633

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.78mL

2.56mL

1.28mL

25.55mL

5.11mL

2.56mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories